TcrossGlobal

Percutaneous Coronary Treatment With Bioadaptor Implant vs Drug-Eluting Stent: 2-Year Outcomes From BIOADAPTOR RCT

The BIOADAPTOR trial demonstrated that at 2-year follow-up, PCI using the DynamX sirolimus-eluting bioadaptor resulted in fewer target lesion failure (TLF; a composite of cardiovascular death, target vessel myocardial infarction, or clinically driven target lesion revascularization) events compared with conventional DES, Dr. Shigeru Saito and colleagues, Shonan Kamakura General Hospital, Japan, reported in the April 28 issue of JACC: Cardiovascular Interventions.

The researchers evaluated the outcomes at two years in the BIOADAPTOR trial, in which 445 patients u...

Continue reading this article

Select an option below:

Free Registration
Already have an account?
Log In

Introducing the main contents

Conference Reports

Timely delivery of scientific meetings from around the world, including AHA, ESC, TCT, EuroPCR, JCC, etc!

Complex PCI Cases

Features case reports on patients with complex lesions encountered in daily clinical practice.

Live Demonstration CoursesComing soon

In this section you will find live videos of catheter interventions for complex lesions.

What is TCROSS NEWS GLOBAL?

TCROSS NEWS Global, an affiliate of TCROSS Co., Ltd. Japan(established in 2005) is a cardiovascular news website which serves as a link between cardiologists, medical device manufacturers and industry stakeholders.
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.

Learn more about TCROSS NEWS Global

This website is automatically translated using Google Translate.